SAFETY OF V116, A 21 VALENT ADULT-SPECIFIC PNEUMOCOCCAL CONJUGATE VACCINE, IN ADULTS ≥18 YEARS: A POOLED SECONDARY ANALYSIS FROM THE PHASE 3 PROGRAM (ID 851)

Park J, Fernsler D, Shi Z, Platt H, and Esteves-Jaramillo A. Presented on behalf of the authors by Patel J.

MSD (UK)

This work was previously presented at ISPPD-14 in Copenhagen, Denmark, on 17-21 May 2026

Funding: This work was funded by Merck & Co., Inc., Rahway, NJ, USA

Conflicts of interest: The authors are employees of Merck & Co., Inc., Rahway, NJ, USA and MSD (UK) Limited, London, UK